Monthly Archives: September 2018

Power Integrations, Inc. v. Fairchild Semiconductor Int., et al.

Docket No. 2016-2691, 2017-1875 DYK, CLEVENGER, CHEN July 3, 2018 (updated September 25, 2018) Update: Original opinion modified on Sept. 20, 2018 following a petition for rehearing filed by Power Integrations (PI) but the same decisions were reached (DC claim … Continue reading

Posted in Claim Construction, Damages, Doctrine of equivalents, Infringement, Royalties | Leave a comment

ParkerVision, Inc. v. Qualcomm Inc. et al.

Docket No. 2017-2012, -2013, -2014, 2074 (IPR2015-01828, -01829, -01831) O’MALLEY, REYNA, TARANTO September 13, 2018 Brief summary: Board’s IPR decisions finding certain claims of PV’s patent relating to cellular phones obvious affirmed (e.g., “[a]ny motivation to combine references, whether articulated … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

E.I. DuPont De Nemours & Co. et al. v. Synvina C.V.

Docket No. 2017-1977 (IPR2015-01838) LOURIE, O’MALLEY, CHEN September 17, 2018 Brief summary: FC panel reversed the Board IPR decision of nonobviousness, writing that “this case involves a strong case of obviousness based on very close prior art and weak evidence … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

Nobel Biocare Services AG v. Instradent USA, Inc.

Docket No. 2017-2259 (IPR2015-01786) PROST, LOURIE, CHEN September 13, 2018 Brief summary: Board IPR decision finding Nobel’s claims relating to dental implants are invalid for anticipation affirmed, based in part on finding that trade show catalog was publicly available under … Continue reading

Posted in Anticipation (35 USC 102), Inter Parties Review (IPR), IPR | Leave a comment

Orexo AB et al. v. Actavis Elizabeth LLC

Docket No. 2017-1333 NEWMAN, HUGHES, STOLL September 10, 2018 Brief summary: DC holding of Orexo’s Orange Book-listed claims related to the opioid dependence drug Zubsolv® invalid for obviousness reversed and remanded. Summary: Orexo appealed DC holding of claims 1, 3-6 … Continue reading

Posted in Generics / ANDA, Obviousness | Leave a comment

Acorda Therapeutics, Inc. / Alkermes Pharma v. Roxane / Mylan / Teva (“Defendants”)

Docket No. 2017-2078, -2134 NEWMAN (D), DYK, TARANTO September 10, 2018 Brief summary: DC invalidation of four Orange Book (“OB”) patents relating to Acorda’s Ampyra® product for obviousness affirmed. Summary: Acorda appealed DC finding that the claims of its four … Continue reading

Posted in Generics / ANDA, Obviousness, Obviousness-Teaching Away | Leave a comment

Regents of The University of California, University of Vienna, Emmanuelle Charpentier (“UC”) v. Broad Institute, Inc., Mass. Inst. Tech., Fellows of Harvard College (“Broad”)

Docket No. 2017-1907 PROST, SCHALL, MOORE September 10, 2018 Brief summary: FC panel affirmed the Board’s judgment of no interference-in-fact between UC’s and Broad’s claims, also stating that this “is not a ruling on the validity of either set of … Continue reading

Posted in Interference, Obviousness | Leave a comment